Search Results

You are looking at 1 - 10 of 32 items for :

  • By Author: Wu, Jau-Ching x
Clear All
Restricted access

Cheerag D. Upadhyaya, Jau-Ching Wu, Gregory Trost, Regis W. Haid, Vincent C. Traynelis, Bobby Tay, Domagoj Coric and Praveen V. Mummaneni

these trials participated in this analysis. The coauthors had access to unpublished as well as published summary data from each of these trials. We obtained unpublished, original summary data from each of the trials to complete our analysis. Statistics were calculated utilizing fixed effects and random effects assumptions to calculate a pooled RR for categorical variables and WMD for continuous variables. A random effects model typically yields a more conservative effect estimate. Given that the trials were studying different devices, we thought it prudent to use

Full access

Peng-Yuan Chang, Hsuan-Kan Chang and Jau-Ching Wu

TO THE EDITOR: We read with great interest the article by Dr. Heary and colleagues 8 in the December issue of the Journal of Neurosurgery: Spine (Heary RF, Goldstein IM, Getto KM, et al: Solid radiographic fusion with a nonconstrained device 5 years after cervical arthroplasty. J Neurosurg Spine 21: 951–955, December 2014). The authors reported the case of a patient who underwent cervical disc arthroplasty (CDA) using the DISCOVER artificial disc (DePuy Synthes Spine Inc.). Five years after the surgery, spontaneous fusion at the surgical level was

Free access

Yu-Chun Chen, Chao-Hung Kuo, Chieh-Ming Cheng and Jau-Ching Wu

. Although the outcomes of ACDF have been extraordinarily good, it still has drawbacks: there has been a potential risk of inducing iatrogenic CSM over the adjacent levels of fusions. 28 Therefore, the emerging technology of CDA has offered an alternative option of preservation of disc mobility, which stabilizes the spine after discectomy. It has been widely accepted for years that CDA provided equal therapeutic outcome with arthrodesis for patients with single-level cervical myelopathy. There were also prospective multicenter randomized controlled trials on many devices

Restricted access

Tsung-Hsi Tu, Jau-Ching Wu, Li-Yu Fay, Chin-Chu Ko, Wen-Cheng Huang and Henrich Cheng

C ervical TDR has recently been regarded as an alternative surgical treatment for degenerative disc disease. Compared with the standard ACDF, cervical TDR preserves segmental motion, and the theoretical potential to decrease adjacent-segment disease is thus anticipated. Randomized controlled clinical trials of a number of cervical TDR devices, with a maximum follow-up duration of 5 years, have been published. 2–4 , 6 , 8–11 , 13 These trials all concluded that cervical TDR is a safe and effective alternative to ACDF for single-level cervical spondylosis

Restricted access

Tsung-Hsi Tu, Jau-Ching Wu, Wen-Cheng Huang, Ching-Lan Wu, Chin-Chu Ko and Henrich Cheng

cervical arthroplasty. Interestingly, the reported incidence rates of HO development are substantially inconsistent in different series, ranging from none to more than two-thirds of the treated levels. 2 , 3 , 6 , 8 , 12 , 15 , 17 , 18 , 29 , 34 The true cause of these widely variable incidences of HO in the literature remains elusive. This disparity can be attributed to the design and the material of devices, timing and method of evaluation, the use of NSAIDs, or idiosyncrasy. Furthermore, the long-term effects of HO on clinical outcomes are still uncertain and require

Restricted access

Jau-Ching Wu, Wen-Cheng Huang, Tsung-Hsi Tu, Hsiao-Wen Tsai, Chin-Chu Ko, Ching-Lan Wu and Henrich Cheng

F or decades, ACDF has been the gold standard in surgical treatment for various cervical disc diseases. Several degenerative cervical spine problems, including single- or multilevel disc diseases, spondylotic radiculopathy or myelopathy, ossification of the posterior longitudinal ligament, and kyphotic deformity, can be managed with ACDF. 2 , 8 , 16 , 17 , 29 In the last decade, there emerged the option of cervical arthroplasty, which replaces the pathological disc with a mechanical device to preserve joint function. Several of these artificial discs have

Full access

Tsung-Hsi Tu, Chao-Hung Kuo, Wen-Cheng Huang, Li-Yu Fay, Henrich Cheng and Jau-Ching Wu

after anterior cervical discectomy and thus ameliorate the development of ASD. During the past decade, data from US Food and Drug Administration (FDA) clinical trials comparing 1- and 2-level CDA to ACDF have demonstrated equal or superior results for CDA in terms of improvement in neurological function and in the reduction of secondary surgery. 14 , 15 , 18 Much of the literature agrees that these CDA devices can successfully maintain segmental mobility at an average of about 7°–8° during flexion and extension. However, it remains questionable if the CDA can

Full access

Chao-Hung Kuo, Wen-Cheng Huang, Jau-Ching Wu, Tsung-Hsi Tu, Li-Yu Fay, Ching-Lan Wu and Henrich Cheng

MI-TLIF, supporting the theoretical effects of DDS on the deceleration of degeneration. However, because of the low incidence of ASD shortly after the operations, a long enough follow-up—for example, 10 to 15 years—may be necessary to differentiate the true effects of these two treatment modalities. Whether the ASD was device related or a natural course remains undetermined since the study did not have a control group that did not undergo surgery. Results of the current study obviously suggest the need for greater case numbers and a longer duration (at least 5

Full access

Jau-Ching Wu, Wen-Cheng Huang, Hsiao-Wen Tsai, Chin-Chu Ko, Ching-Lan Wu, Tsung-Hsi Tu and Henrich Cheng

dynamic stabilization device. Future studies with stratification of each specific indication for the dynamic stabilization device are necessary to clarify its optimal application. There are limitations to this study. This cohort was composed of patients with lumbar spondylosis of various kinds, including unstable stenosis, degenerative disc disease, mild spondylolisthesis, recurrent disc herniation, and iatrogenic instability. The surgical indications for dynamic stabilization in the study were not uniform, which might contribute differently to screw loosening. The

Restricted access

Tsung-Hsi Tu, Jau-Ching Wu, Wen-Cheng Huang, Wan-Yuo Guo, Ching-Lan Wu, Yang-Hsin Shih and Henrich Cheng

, data from the 2-year follow-up of the Bryan FDA investigational device exemption trial showed no spontaneous fusion at 2 years. 12 The authors attributed the excellent mobility of the artificial discs to the prescription of NSAIDs for 2 weeks postoperatively, as well as patient selection to exclude those with severe spondylosis, in whom fusion was more likely. In the current study, 1-week postoperative NSAID treatment was chosen as a balance between HO prevention and NSAID side effects. However, to date, there is still no solid evidence regarding the effect of